ES2517925T3 - Utilización de activadores de canales potásicos K2P como analgésicos - Google Patents

Utilización de activadores de canales potásicos K2P como analgésicos Download PDF

Info

Publication number
ES2517925T3
ES2517925T3 ES10771161.6T ES10771161T ES2517925T3 ES 2517925 T3 ES2517925 T3 ES 2517925T3 ES 10771161 T ES10771161 T ES 10771161T ES 2517925 T3 ES2517925 T3 ES 2517925T3
Authority
ES
Spain
Prior art keywords
trek
effect
morphine
potassium channel
analgesic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10771161.6T
Other languages
English (en)
Spanish (es)
Inventor
Alain Eschalier
Jérôme BUSSEROLLES
Abdelkrim Alloui
Michel Lazdunski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Clermont Auvergne
Original Assignee
Université Clermont Auvergne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Clermont Auvergne filed Critical Université Clermont Auvergne
Application granted granted Critical
Publication of ES2517925T3 publication Critical patent/ES2517925T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES10771161.6T 2009-09-21 2010-09-21 Utilización de activadores de canales potásicos K2P como analgésicos Active ES2517925T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0956477A FR2950362B1 (fr) 2009-09-21 2009-09-21 Utilisation d'activateurs de canaux potassiques k2p en tant qu'antalgiques.
FR0956477 2009-09-21
PCT/FR2010/051968 WO2011033241A1 (fr) 2009-09-21 2010-09-21 Utilisation d'activateurs de canaux potassiques k2p en tant qu'antalgiques

Publications (1)

Publication Number Publication Date
ES2517925T3 true ES2517925T3 (es) 2014-11-04

Family

ID=42115665

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10771161.6T Active ES2517925T3 (es) 2009-09-21 2010-09-21 Utilización de activadores de canales potásicos K2P como analgésicos

Country Status (9)

Country Link
US (1) US9448242B2 (enExample)
EP (1) EP2480893B1 (enExample)
CN (1) CN102597780B (enExample)
CA (1) CA2774861C (enExample)
DK (1) DK2480893T3 (enExample)
ES (1) ES2517925T3 (enExample)
FR (1) FR2950362B1 (enExample)
IN (1) IN2012DN02433A (enExample)
WO (1) WO2011033241A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013098416A2 (fr) 2011-12-30 2013-07-04 Ecole Nationale Superieure De Chimie De Clermont Ferrand Composes anti-douleur
WO2024126778A1 (en) * 2022-12-16 2024-06-20 Centre National De La Recherche Scientifique Process for reversibly inhibiting two-pore potassium channels and inducing nociception, with light spatiotemporal resolution

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1192126A (en) * 1967-10-05 1970-05-20 Centre Nat Rech Scient Indole Derivatives and their production
FR2623498B1 (fr) * 1987-11-24 1990-04-06 Bioprojet Soc Civ Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques
US20030165806A1 (en) * 1997-03-11 2003-09-04 Mark H. Pausch Potassium channels, nucleotide sequences encoding them, and methods of using same
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US7112403B1 (en) * 1998-09-01 2006-09-26 Centre National De La Recherche Scientifique Method for the identification of anesthetics
US7955616B2 (en) * 2003-09-23 2011-06-07 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
GB0329310D0 (en) * 2003-12-18 2004-01-21 Univ Keele Method
EP2077126A1 (en) * 2008-01-07 2009-07-08 Graftys Analgesic apatitic calcium-phosphate cement

Also Published As

Publication number Publication date
CA2774861A1 (fr) 2011-03-24
EP2480893B1 (fr) 2014-08-27
DK2480893T3 (da) 2014-09-29
FR2950362B1 (fr) 2011-10-21
US20120260354A1 (en) 2012-10-11
FR2950362A1 (fr) 2011-03-25
WO2011033241A1 (fr) 2011-03-24
CN102597780A (zh) 2012-07-18
CA2774861C (fr) 2017-08-08
US9448242B2 (en) 2016-09-20
EP2480893A1 (fr) 2012-08-01
CN102597780B (zh) 2014-11-12
IN2012DN02433A (enExample) 2015-08-21

Similar Documents

Publication Publication Date Title
Chu et al. Physiological and pathological functions of acid-sensing ion channels in the central nervous system
Lee et al. Inhibition of acid‐sensing ion channels by diminazene and APETx2 evoke partial and highly variable antihyperalgesia in a rat model of inflammatory pain
Bilsky et al. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Huang et al. Ketamine potentiates hippocampal neurodegeneration and persistent learning and memory impairment through the PKCγ–ERK signaling pathway in the developing brain
Lau et al. Opioid presynaptic disinhibition of the midbrain periaqueductal grey descending analgesic pathway
EP0625162B1 (en) Methods of producing analgesia and enhancing opiate analgesia
Broom et al. Comparison of receptor mechanisms and efficacy requirements for δ-agonist-induced convulsive activity and antinociception in mice
ES2693761T3 (es) Composiciones de péptidos
HK1251472A1 (zh) 治疗痛觉过敏的方法
Logue et al. Sex-specific effects of social isolation stress and ketamine on hippocampal plasticity
Sacchetti et al. Chronic treatment with desipramine facilitates its effect on extracellular noradrenaline in the rat hippocampus: studies on the role of presynaptic α2-adrenoceptors
ES2385138T3 (es) Modelo de roedor de enfermedad para dolor muscular crónico
Sutovska et al. Pharmacodynamic evaluation of RP3128, a novel and potent CRAC channel inhibitor in guinea pig models of allergic asthma
Lattanzi et al. Pharmacological activity of a Bv8 analogue modified in position 24
Garduño-Gutiérrez et al. Different amounts of ejaculatory activity, a natural rewarding behavior, induce differential mu and delta opioid receptor internalization in the rat's ventral tegmental area
US20150329608A1 (en) Opiorphin for use as a psychostimulant agent
Fioravanti et al. The ORL-1 receptor system: are there opportunities for antagonists in pain therapy?
Costanzini et al. Pharmacological characterization of naloxegol: In vitro and in vivo studies
US9448242B2 (en) Use of K2P potassium channel activators as antalgics
Zielińska et al. Methyl-orvinol—Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome
Petrenko et al. Effects of ketamine on acute somatic nociception in wild-type and N-methyl-d-aspartate (NMDA) receptor ɛ1 subunit knockout mice
CN109475552B (zh) 用于食欲控制和体重管理的方法和组合物
Chen et al. Rat NPFF1 receptor-mediated signaling: functional comparison of neuropeptide FF (NPFF), FMRFamide and PFR (Tic) amide
Mastropaolo et al. Arginine vasopressin, via activation of post-junctional V1 receptors, induces contractile effects in mouse distal colon
Ronsisvalle et al. CCB, a novel specific κ opioid agonist, which discriminates between opioid and σ1 recognition sites